Corpus Intelligence IC Memo — TUCSON MEDICAL CENTER 2026-04-26 04:03 UTC
IC Memo — TUCSON MEDICAL CENTER
Investment Committee Memorandum | AZ | 499 beds | Grade C | EBITDA uplift $55.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TUCSON MEDICAL CENTER

CCN 030006 | PIMA, AZ | 499 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

TUCSON MEDICAL CENTER is a 499-bed safety-net/medicaid heavy in PIMA, AZ with $747.4M in net patient revenue and a -2.8% operating margin. The hospital serves a payer mix of 20.1% Medicare, 33.9% Medicaid, and 46.0% commercial.

Thesis: Undervalued. Our ML models identify $55.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.8% to 4.6% (+736bps).

Net Revenue HCRIS$747.4M
Current EBITDA COMPUTED$-20.9M
Operating Margin COMPUTED-2.8%
Occupancy HCRIS86.3%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS25.8%
Distress Probability ML47.2%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
21
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of -2.8% places it below the state median. Among 21 size-comparable peers (250-998 beds), the median margin is -1.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (250-998), prioritizing same-state peers. 21 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TUCSON MEDICAL CENTER (Target)AZ499$747.4M-2.8%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
BANNER ESTRELLA MEDICAL CENTERAZ317$1.84B79.2%
BANNER BAYWOOD MEDICAL CENTERAZ323$1.39B79.1%
ST. JOSEPHS HOSPITAL & MEDICALAZ515$1.31B-17.7%
PHOENIX CHILDRENS HOSPITALAZ352$1.26B6.0%
BANNER UNIVERSITY MEDICAL CENTAZ656$1.09B-5.9%
BANNER UNIVERSITY MED CENTER TAZ533$1.03B-4.6%
BANNER DESERT MEDICAL CENTERAZ629$833.1M12.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $55.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$15.7M+210bp18mo
Cost to Collect4.5%2.5%$14.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$14.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$9.1M+122bp9mo
Clean Claim Rate88.0%96.0%$478K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$15.7M
Cost to Collect
$14.9M
Denial Rate Reduction
$14.8M
A/R Days Reduction
$9.1M
Clean Claim Rate
$478K
Total EBITDA Uplift$55.0M
Current EBITDA$-20.9M
+ RCM Uplift+$55.0M
Pro Forma EBITDA$34.1M
Current Margin-2.8%
Pro Forma Margin4.6%
WC Released (1x)$28.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-32.1M$412.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-32.1M$443.3M0.00x-100.0%
Bull Case9.0x11.0x$-28.9M$614.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-28.9M$661.8M0.00x-100.0%
Bear Case11.0x10.0x$-35.3M$147.9M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-35.3M$151.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (33.9%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 21 hospitals with 250-998 beds
  • Same-state prioritization (n=22)
  • Comp margins: P25=-5.9% / P50=-1.0% / P75=6.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.